Swedish biopharmaceutical company Hansa Biopharma AB (STO:HNSA) announced on Thursday that it has received the 2025 SwedenBIO Award at the SwedenBIO Summit in Stockholm.

This award aims to recognise companies that drive scientific progress, operational excellence, and international impact.

Through its pioneering enzyme technology, Hansa enables life-saving transplantation for highly sensitised patients with previously unmet needs.

Renee Aguiar-Lucander, CEO, Hansa Biopharma said: "I am truly delighted and deeply honoured to receive this award on behalf of everyone at Hansa Biopharma. This recognition reflects the great momentum we've built heading into 2026 -- powered by our strong US Phase 3 data, the upcoming FDA review process, and the anticipated Phase 3 readout from our European Phase 3 trial later this year. Thank you to the SwedenBIO organisation and judges for this recognition. We're proud of how far we've come, and excited for the journey ahead."